These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 28361972)

  • 1. PABPN1 gene therapy for oculopharyngeal muscular dystrophy.
    Malerba A; Klein P; Bachtarzi H; Jarmin SA; Cordova G; Ferry A; Strings V; Espinoza MP; Mamchaoui K; Blumen SC; St Guily JL; Mouly V; Graham M; Butler-Browne G; Suhy DA; Trollet C; Dickson G
    Nat Commun; 2017 Mar; 8():14848. PubMed ID: 28361972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Established PABPN1 intranuclear inclusions in OPMD muscle can be efficiently reversed by AAV-mediated knockdown and replacement of mutant expanded PABPN1.
    Malerba A; Klein P; Lu-Nguyen N; Cappellari O; Strings-Ufombah V; Harbaran S; Roelvink P; Suhy D; Trollet C; Dickson G
    Hum Mol Genet; 2019 Oct; 28(19):3301-3308. PubMed ID: 31294444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitochondrial localization of PABPN1 in oculopharyngeal muscular dystrophy.
    Doki T; Yamashita S; Wei FY; Hara K; Yamamoto T; Zhang Z; Zhang X; Tawara N; Hino H; Uyama E; Kurashige T; Maruyama H; Tomizawa K; Ando Y
    Lab Invest; 2019 Nov; 99(11):1728-1740. PubMed ID: 30894671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress on gene therapy, cell therapy, and pharmacological strategies toward the treatment of oculopharyngeal muscular dystrophy.
    Harish P; Malerba A; Dickson G; Bachtarzi H
    Hum Gene Ther; 2015 May; 26(5):286-92. PubMed ID: 25860803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of PABPN1 nuclear inclusions on a large cohort of patients and in a human xenograft model of oculopharyngeal muscular dystrophy.
    Roth F; Dhiab J; Boulinguiez A; Mouigni HR; Lassche S; Negroni E; Muraine L; Marhic A; Oliver A; Lainé J; Rouche A; O'Ferrall EK; van Engelen B; Ottenheijm C; Greif H; Blumen S; Lacau St Guily J; Perie S; Butler-Browne G; Mouly V; Trollet C
    Acta Neuropathol; 2022 Dec; 144(6):1157-1170. PubMed ID: 36197469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional impact of an oculopharyngeal muscular dystrophy mutation in PABPN1.
    García-Castañeda M; Vega AV; Rodríguez R; Montiel-Jaen MG; Cisneros B; Zarain-Herzberg A; Avila G
    J Physiol; 2017 Jul; 595(13):4167-4187. PubMed ID: 28303574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and phenotypic characterization of a mouse model of oculopharyngeal muscular dystrophy reveals severe muscular atrophy restricted to fast glycolytic fibres.
    Trollet C; Anvar SY; Venema A; Hargreaves IP; Foster K; Vignaud A; Ferry A; Negroni E; Hourde C; Baraibar MA; 't Hoen PA; Davies JE; Rubinsztein DC; Heales SJ; Mouly V; van der Maarel SM; Butler-Browne G; Raz V; Dickson G
    Hum Mol Genet; 2010 Jun; 19(11):2191-207. PubMed ID: 20207626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oculopharyngeal muscular dystrophy: recent advances in the understanding of the molecular pathogenic mechanisms and treatment strategies.
    Abu-Baker A; Rouleau GA
    Biochim Biophys Acta; 2007 Feb; 1772(2):173-85. PubMed ID: 17110089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myopathy phenotype in transgenic mice expressing mutated PABPN1 as a model of oculopharyngeal muscular dystrophy.
    Hino H; Araki K; Uyama E; Takeya M; Araki M; Yoshinobu K; Miike K; Kawazoe Y; Maeda Y; Uchino M; Yamamura K
    Hum Mol Genet; 2004 Jan; 13(2):181-90. PubMed ID: 14645203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of
    Cruz-Aguilar M; Guerrero-de Ferran C; Tovilla-Canales JL; Nava-Castañeda A; Zenteno JC
    J Investig Med; 2017 Mar; 65(3):705-708. PubMed ID: 27980005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoplasmic targeting of mutant poly(A)-binding protein nuclear 1 suppresses protein aggregation and toxicity in oculopharyngeal muscular dystrophy.
    Abu-Baker A; Laganiere S; Fan X; Laganiere J; Brais B; Rouleau GA
    Traffic; 2005 Sep; 6(9):766-79. PubMed ID: 16101680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between PABPN1 genotype and disease severity in oculopharyngeal muscular dystrophy.
    Richard P; Trollet C; Stojkovic T; de Becdelievre A; Perie S; Pouget J; Eymard B;
    Neurology; 2017 Jan; 88(4):359-365. PubMed ID: 28011929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Drosophila model of oculopharyngeal muscular dystrophy reveals intrinsic toxicity of PABPN1.
    Chartier A; Benoit B; Simonelig M
    EMBO J; 2006 May; 25(10):2253-62. PubMed ID: 16642034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranuclear Aggregates Precede Clinical Onset in Oculopharyngeal Muscular Dystrophy.
    van der Sluijs BM; Raz V; Lammens M; van den Heuvel LP; Voermans NC; van Engelen BG
    J Neuromuscul Dis; 2016 Mar; 3(1):101-109. PubMed ID: 27854203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel mouse models of oculopharyngeal muscular dystrophy (OPMD) reveal early onset mitochondrial defects and suggest loss of PABPN1 may contribute to pathology.
    Vest KE; Phillips BL; Banerjee A; Apponi LH; Dammer EB; Xu W; Zheng D; Yu J; Tian B; Pavlath GK; Corbett AH
    Hum Mol Genet; 2017 Sep; 26(17):3235-3252. PubMed ID: 28575395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A decline in PABPN1 induces progressive muscle weakness in oculopharyngeal muscle dystrophy and in muscle aging.
    Anvar SY; Raz Y; Verway N; van der Sluijs B; Venema A; Goeman JJ; Vissing J; van der Maarel SM; 't Hoen PA; van Engelen BG; Raz V
    Aging (Albany NY); 2013 Jun; 5(6):412-26. PubMed ID: 23793615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteomic analysis reveals that wildtype and alanine-expanded nuclear poly(A)-binding protein exhibit differential interactions in skeletal muscle.
    Banerjee A; Phillips BL; Deng Q; Seyfried NT; Pavlath GK; Vest KE; Corbett AH
    J Biol Chem; 2019 May; 294(18):7360-7376. PubMed ID: 30837270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Japanese case of oculopharyngeal muscular dystrophy (OPMD) with PABPN1 c.35G > C; p.Gly12Ala point mutation.
    Nishii YS; Noto YI; Yasuda R; Kitaoji T; Ashida S; Tanaka E; Minami N; Nishino I; Mizuno T
    BMC Neurol; 2021 Jul; 21(1):265. PubMed ID: 34225694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cystamine suppresses polyalanine toxicity in a mouse model of oculopharyngeal muscular dystrophy.
    Davies JE; Rose C; Sarkar S; Rubinsztein DC
    Sci Transl Med; 2010 Jun; 2(34):34ra40. PubMed ID: 20519718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear speckles are involved in nuclear aggregation of PABPN1 and in the pathophysiology of oculopharyngeal muscular dystrophy.
    Bengoechea R; Tapia O; Casafont I; Berciano J; Lafarga M; Berciano MT
    Neurobiol Dis; 2012 Apr; 46(1):118-29. PubMed ID: 22249111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.